IMS Capital Management Sells 1,750 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

IMS Capital Management lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 47.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,950 shares of the company’s stock after selling 1,750 shares during the quarter. IMS Capital Management’s holdings in IDEXX Laboratories were worth $530,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in IDXX. Price T Rowe Associates Inc. MD boosted its position in shares of IDEXX Laboratories by 32.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,180,724 shares of the company’s stock worth $875,749,000 after purchasing an additional 787,736 shares in the last quarter. American Century Companies Inc. boosted its position in shares of IDEXX Laboratories by 111.2% during the 1st quarter. American Century Companies Inc. now owns 1,483,074 shares of the company’s stock worth $331,615,000 after purchasing an additional 780,846 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of IDEXX Laboratories by 27,381.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 568,322 shares of the company’s stock worth $156,476,000 after purchasing an additional 566,254 shares in the last quarter. Marshall Wace North America L.P. boosted its position in shares of IDEXX Laboratories by 1,086.6% during the 1st quarter. Marshall Wace North America L.P. now owns 404,041 shares of the company’s stock worth $90,344,000 after purchasing an additional 369,991 shares in the last quarter. Finally, Invesco Ltd. lifted its position in IDEXX Laboratories by 28.2% in the 2nd quarter. Invesco Ltd. now owns 1,472,407 shares of the company’s stock valued at $405,398,000 after acquiring an additional 323,919 shares in the last quarter. 86.69% of the stock is currently owned by institutional investors.

NASDAQ IDXX traded up $4.19 during trading hours on Wednesday, hitting $271.91. The company’s stock had a trading volume of 185,563 shares, compared to its average volume of 447,195. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 4.49. The company has a market capitalization of $23.81 billion, a PE ratio of 63.83 and a beta of 0.82. IDEXX Laboratories, Inc. has a 52 week low of $176.11 and a 52 week high of $292.17. The company’s 50-day simple moving average is $276.56 and its two-hundred day simple moving average is $261.17.



IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, August 1st. The company reported $1.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.06. The firm had revenue of $620.10 million during the quarter, compared to analyst estimates of $627.10 million. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter last year, the business posted $1.23 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 4.86 EPS for the current fiscal year.

In other IDEXX Laboratories news, insider Jay Mazelsky sold 10,000 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $258.40, for a total value of $2,584,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Jonathan W. Ayers sold 20,000 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.26, for a total transaction of $5,245,200.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,305 shares of company stock valued at $19,402,442. Company insiders own 2.70% of the company’s stock.

Several equities analysts recently weighed in on IDXX shares. ValuEngine cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research report on Monday, September 9th. They issued a “neutral” rating and a $277.00 price target on the stock. Bank of America set a $300.00 price target on shares of IDEXX Laboratories and gave the company a “buy” rating in a research report on Friday, June 21st. Credit Suisse Group raised their price target on shares of IDEXX Laboratories from $282.00 to $293.00 and gave the company an “outperform” rating in a research report on Friday, August 16th. Finally, Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $285.29.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: What is the strike price in options trading?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.